Literature DB >> 22496154

Prediction of cytogenetic abnormalities with gene expression profiles.

Yiming Zhou1, Qing Zhang, Owen Stephens, Christoph J Heuck, Erming Tian, Jeffrey R Sawyer, Marie-Astrid Cartron-Mizeracki, Pingping Qu, Jason Keller, Joshua Epstein, Bart Barlogie, John D Shaughnessy.   

Abstract

Cytogenetic abnormalities are important clinical parameters in various types of cancer, including multiple myeloma. We developed a model to predict cytogenetic abnormalities in patients with multiple myeloma using gene expression profiling and validated it by different cytogenetic techniques. The model has an accuracy rate up to 0.89. These results provide proof of concept for the hypothesis that gene expression profiling is a superior genomic method for clinical molecular diagnosis and/or prognosis.

Entities:  

Mesh：

Year:  2012        PMID： 22496154      PMCID： PMC3367903          DOI： 10.1182/blood-2011-10-388702

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Assessing the accuracy of prediction algorithms for classification: an overview.

Authors:  P Baldi; S Brunak; Y Chauvin; C A Andersen; H Nielsen
Journal:  Bioinformatics       Date:  2000-05       Impact factor: 6.937

2.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Authors:  Fenghuang Zhan; Johanna Hardin; Bob Kordsmeier; Klaus Bumm; Mingzhong Zheng; Erming Tian; Ralph Sanderson; Yang Yang; Carla Wilson; Maurizio Zangari; Elias Anaissie; Christopher Morris; Firas Muwalla; Frits van Rhee; Athanasios Fassas; John Crowley; Guido Tricot; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

3.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation.

Authors:  Yee Hwa Yang; Sandrine Dudoit; Percy Luu; David M Lin; Vivian Peng; John Ngai; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

4.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Authors:  Kai Neben; Henk M Lokhorst; Anna Jauch; Uta Bertsch; Thomas Hielscher; Bronno van der Holt; Hans Salwender; Igor W Blau; Katja Weisel; Michael Pfreundschuh; Christof Scheid; Ulrich Dührsen; Walter Lindemann; Ingo G H Schmidt-Wolf; Norma Peter; Christian Teschendorf; Hans Martin; Mathias Haenel; Hans G Derigs; Marc S Raab; Anthony D Ho; Helgi van de Velde; Dirk Hose; Pieter Sonneveld; Hartmut Goldschmidt
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

Review 5.  Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Authors:  A Keith Stewart; Rafael Fonseca
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

6.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

7.  Prognostic value of cytogenetics in multiple myeloma.

Authors:  C Seong; K Delasalle; K Hayes; D Weber; M Dimopoulos; J Swantkowski; Y Huh; A Glassman; R Champlin; R Alexanian
Journal:  Br J Haematol       Date:  1998-04       Impact factor: 6.998

8.  Cytogenetic findings in 200 patients with multiple myeloma.

Authors:  J R Sawyer; J A Waldron; S Jagannath; B Barlogie
Journal:  Cancer Genet Cytogenet       Date:  1995-07-01

Review 9.  Multiple myeloma: evolving genetic events and host interactions.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

10.  p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

Authors:  Hong Chang; Connie Qi; Qi-Long Yi; Donna Reece; A Keith Stewart
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113
View more
  19 in total

1.  Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.

Authors:  Dongjun Lee; Ying-Hua Wang; Demetrios Kalaitzidis; Janani Ramachandran; Homare Eda; David B Sykes; Noopur Raje; David T Scadden
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

2.  Reduced rank regression via adaptive nuclear norm penalization.

Authors:  Kun Chen; Hongbo Dong; Kung-Sik Chan
Journal:  Biometrika       Date:  2013-12-04       Impact factor: 2.445

3.  Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery.

Authors:  M H Ung; C-H Sun; C-W Weng; C-C Huang; C-C Lin; C-C Liu; C Cheng
Journal:  Pharmacogenomics J       Date:  2016-03-15       Impact factor: 3.550

4.  Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Authors:  S W Erickson; O W Stephens; S S Chavan; E Tian; J Epstein; B Barlogie; C J Heuck; A J Vangsted
Journal:  Leukemia       Date:  2015-08-26       Impact factor: 11.528

5.  Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Authors:  Christoph J Heuck; Jackie Szymonifka; Emily Hansen; John D Shaughnessy; Saad Z Usmani; Frits van Rhee; Elias Anaissie; Bijay Nair; Sarah Waheed; Yazan Alsayed; Nathan Petty; Clyde Bailey; Joshua Epstein; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Clin Cancer Res       Date:  2012-08-01       Impact factor: 12.531

6.  Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma.

Authors:  Bachisio Ziccheddu; Matteo C Da Vià; Francesco Maura; Niccolò Bolli; Marta Lionetti; Akihiro Maeda; Silvia Morlupi; Matteo Dugo; Katia Todoerti; Stefania Oliva; Mattia D'Agostino; Paolo Corradini; Ola Landgren; Francesco Iorio; Loredana Pettine; Alessandra Pompa; Martina Manzoni; Luca Baldini; Antonino Neri
Journal:  Clin Cancer Res       Date:  2021-09-15       Impact factor: 12.531

7.  Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

Authors:  Ryan van Laar; Rachel Flinchum; Nathan Brown; Joseph Ramsey; Sam Riccitelli; Christoph Heuck; Bart Barlogie; John D Shaughnessy
Journal:  BMC Med Genomics       Date:  2014-05-17       Impact factor: 3.063

8.  A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships.

Authors:  Richard Newton; Lorenz Wernisch
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

9.  Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles.

Authors:  Yingxiang Li; Xujun Wang; Haiyang Zheng; Chengyang Wang; Stéphane Minvielle; Florence Magrangeas; Hervé Avet-Loiseau; Parantu K Shah; Yong Zhang; Nikhil C Munshi; Cheng Li
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

10.  Investigating inter-chromosomal regulatory relationships through a comprehensive meta-analysis of matched copy number and transcriptomics data sets.

Authors:  Richard Newton; Lorenz Wernisch
Journal:  BMC Genomics       Date:  2015-11-18       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.